Dr. Charles Newman to head Riverview wound center

Dr. Charles Newman has been appointed medical director for Riverview Wound Care and Hyperbaric Center.

Dr. Charles Newman

Newman, a specialist in general and vascular surgery, is a familiar face in Etowah County medicine, with more than 20 years of service to the community.

He attended the University of Alabama School of Medicine and completed his surgical residency at Georgia Baptist Medical Center in 1995.

Newman is on the board of directors for East Alabama Emergency Medical Services Inc. and is chairman of East Alabama Regional Trauma Advisory Council. He also has served as chief of surgery at Riverview Regional Medical Center.

Equinox Medical, LLC Halo MINI NPWT PUMP SYSTEM IS AFFORDABLE AND PORTABLE

Dr. Lucian Newman Jr., specialist in general, vascular surgery and wound care, and Dr. Steven Bayer, wound care specialist, also have joined the center’s medical staff. They collectively have more than 80 years of surgical and practice experience. They join Dr. William Beekley, general surgeon, at the center.

Lucian Newman has been in practice in Etowah County for more than 30 years. He graduated from the University of Alabama School of Medicine and completed his surgical residency at University Hospital in Birmingham in 1966. He has served as chief of staff at Riverview and also is a past president of the Alabama Chapter of the American College of Surgeons.

Bayer is a graduate of Vanderbilt University and received his medical degree and training through the Uniformed Services medical school in Bethesda, Md.

Barclays Reaffirms “Overweight” Rating for Smith & Nephew plc (SN)

Smith & Nephew plc (LON:SN)‘s stock had its “overweight” rating reiterated by analysts at Barclays in a research note issued to investors on Wednesday, MarketBeat.Com reports. They currently have a GBX 1,230 ($19.27) target price on the stock. Barclays’ price objective points to a potential upside of 10.51% from the company’s previous close.

Shares of Smith & Nephew plc (LON:SN) opened at 1113.00 on Wednesday. The stock has a 50 day moving average of GBX 1,151.94 and a 200-day moving average of GBX 1,143.46. Smith & Nephew plc has a 52-week low of GBX 881.00 and a 52-week high of GBX 1,216.00. The stock’s market capitalization is GBX 9.95 billion.

In other Smith & Nephew plc news, insider Barlow ,Ian acquired 153 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average cost of GBX 1,188 ($18.61) per share, for a total transaction of £1,817.64 ($2,848.07).

Other equities analysts have also issued reports about the company. Numis Securities Ltd upgraded Smith & Nephew plc to an “add” rating and set a GBX 1,242 ($19.46) price objective on the stock in a report on Monday, June 1st. JPMorgan Chase & Co. restated a “neutral” rating and issued a GBX 1,069 ($16.75) target price (up previously from GBX 1,040 ($16.30)) on shares of Smith & Nephew plc in a research note on Thursday, July 30th. Deutsche Bank reiterated a “buy” rating and set a GBX 1,250 ($19.59) price objective on shares of Smith & Nephew plc in a research note on Tuesday, July 21st. Berenberg Bank reissued a “buy” rating and set a GBX 1,275 ($19.98) target price on shares of Smith & Nephew plc in a report on Friday, July 31st. Finally, AlphaValue reaffirmed a “buy” rating and issued a GBX 1,304 ($20.43) price objective on shares of Smith & Nephew plc in a report on Thursday, July 2nd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of GBX 1,217.15 ($19.07).

Smith & Nephew plc is a global medical devices business running in the markets for complex surgical apparatus, which includes complex wound management and orthopedic trauma reconstruction and sports medicine. The Business operates in two sections: Advanced Surgical Devices and Advanced Wound Management. The Company’s Advanced Surgical Devices (LON:SN) segment offers products and technologies, including orthopedic reconstruction, trauma and extremities, sports medicine joint repair, arthroscopy enabling technologies as well as other advanced surgical devices (ASD). The Business ‘s Advanced Wound Management (AWM) segment offers products, including Advanced Wound Care, Complex Wound Apparatus and Advanced Wound Bioactives. The Business runs throughout the entire world and has distribution channels in over 100 nations.
Smith & Nephew plc (LON:SN)‘s stock had its “overweight” rating reiterated by analysts at Barclays in a research note issued to investors on Wednesday, MarketBeat.Com reports. They currently have a GBX 1,230 ($19.27) target price on the stock. Barclays’ price objective points to a potential upside of 10.51% from the company’s previous close.

Shares of Smith & Nephew plc (LON:SN) opened at 1113.00 on Wednesday. The stock has a 50 day moving average of GBX 1,151.94 and a 200-day moving average of GBX 1,143.46. Smith & Nephew plc has a 52-week low of GBX 881.00 and a 52-week high of GBX 1,216.00. The stock’s market capitalization is GBX 9.95 billion.

In other Smith & Nephew plc news, insider Barlow ,Ian acquired 153 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average cost of GBX 1,188 ($18.61) per share, for a total transaction of £1,817.64 ($2,848.07).

Other equities analysts have also issued reports about the company. Numis Securities Ltd upgraded Smith & Nephew plc to an “add” rating and set a GBX 1,242 ($19.46) price objective on the stock in a report on Monday, June 1st. JPMorgan Chase & Co. restated a “neutral” rating and issued a GBX 1,069 ($16.75) target price (up previously from GBX 1,040 ($16.30)) on shares of Smith & Nephew plc in a research note on Thursday, July 30th. Deutsche Bank reiterated a “buy” rating and set a GBX 1,250 ($19.59) price objective on shares of Smith & Nephew plc in a research note on Tuesday, July 21st. Berenberg Bank reissued a “buy” rating and set a GBX 1,275 ($19.98) target price on shares of Smith & Nephew plc in a report on Friday, July 31st. Finally, AlphaValue reaffirmed a “buy” rating and issued a GBX 1,304 ($20.43) price objective on shares of Smith & Nephew plc in a report on Thursday, July 2nd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of GBX 1,217.15 ($19.07).

Smith & Nephew plc is a global medical devices business running in the markets for complex surgical apparatus, which includes complex wound management and orthopedic trauma reconstruction and sports medicine. The Business operates in two sections: Advanced Surgical Devices and Advanced Wound Management. The Company’s Advanced Surgical Devices (LON:SN) segment offers products and technologies, including orthopedic reconstruction, trauma and extremities, sports medicine joint repair, arthroscopy enabling technologies as well as other advanced surgical devices (ASD). The Business ‘s Advanced Wound Management (AWM) segment offers products, including Advanced Wound Care, Complex Wound Apparatus and Advanced Wound Bioactives. The Business runs throughout the entire world and has distribution channels in over 100 nations.

Post Acute Care – Marketing Manager for Hire – Acelity

Acelity is a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. They are committed to advancing the science of healing and restoring people’s lives. Acelity has a reach across more than 75 countries; its innovative and complementary product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people around the world.

To continue the growth and innovation of their first in class products, there is an opportunity for the role of:

Marketing Manager – Post-Acute (Wound Care)

Location: Home Office (anywhere in Europe)

Competitive Salary + excellent benefits

Responsibilities

  • Responsible for contributing towards the development and delivery of the Acelity Post-Acute Strategic Marketing plan
  • Work collaborative with all local marketing teams to gain understanding, adapt EU Strategy and drive execution in local markets.
  • Prepare and develop business marketing plans in line with the company goals and objectives, both in respect of revenues as well as market growth and penetration
  • Execute day-to-day management of product portfolio, including inventory management, forecasting, reporting, product improvement initiatives, and future product configurations.
  • Provide daily support and work closely with the sales team across Developed Markets including tools and strategies as appropriate
  • Develop Launch plans for future products including understanding or other applications, channels and devices
  • Ensure consistency of the brand across applications and geographies
  • Up to 50-60% travel across the Developed Markets

Requirements

  • Degree level or equivalent in Marketing or Healthcare related science is of advantage
  • Minimum of 3-5 years of Marketing Management experience
  • Possesses demonstrable and proven seasoned experience in marketing or clinical marketing for medical device or pharmaceutical firms
  • Experience in post-acute sales environment
  • Knowledge and understanding of reimbursement is advantageous
  • As a person you demonstrate strong interpersonal and influential skills
  • You are a highly motivated and driven individual, who exudes integrity, who works in a creative manner when formulating concepts.

If you feel that this is the right move for you and want to join a reputable and growing international business then please apply below or contact us at Mercuri Urval.

Wound Nurse Needed at Alden Park in Rockford, IL

Wound Care Nurse at Alden Park in Rockford, IL

brief Overview/Description

Wound care nurses specialize in the proper management of wound care by treating and monitoring wounds that are the result of disease, injury, or medical treatments.provide care that will quickly and safely heal various types of wounds, including surgical openings, ulcers, bed sores, feeding tube sites, and abscesses.

Position Requirements

Provide standards of practice for the WOC nurse to insure quality patient care services. 2. Provide continuing nursing education for the professional development of the WOC specialty nurse. 3. Represent and promote WOC specialty nursing practice to the public, to allied health care professionals, the community and governmental groups. Accredit Wound, Ostomy, and Continence Nursing Education Programs (WOCNEP). 5. Provide quality continuing education in the field of WOC specialty nursing to other health care providers. 6. Promote ongoing development of the profession and the association through research and long-range planning activities.

Full or Part Time

Facility InformationAlden Park Strathmoor5668 Strathmoor Drive
Rockford, IL 61107

Wound nurses prefer to use negative pressure wound therapy pump system and black foam dressing to extract excess exudate off the wound. NPWT helps balance moisture inside the wound.


Quebec strawberry has potential to reduce Type 2 diabetes risk

Quebec may be known for maple syrup and poutine, however maybe soon strawberries can be added to the rundown. A varietal known as the Authentic Orleans strawberry seems to help diminish the danger of creating Type 2 diabetes.

Developed on the Île d’Orléans—an island on the St. Lawrence River not a long way from downtown Québec City—the delicious, red berry contains a more prominent amassing of specific cancer prevention agents than conventional mixtures, its makers claim.

The strawberry was as of late the center of a clinical trial headed by researchers from Laval University and the Center hospitalier de l’Université Laval. Sixty individuals took an interest, expending either a concentrate rich in polyphenols got from cranberries and Authentic Orleans strawberries or a placebo over a six-week period.

The outcomes demonstrated that expending the Orleans-strawberry concentrate lessened insulin resistance by around 20 for each penny and enhanced glucose administration in stout individuals and those at danger of creating Type 2 diabetes.

“The clinical study demonstrated that the strawberries with cranberries decreased insulin resistance fundamentally,” says André Gosselin, educator of agriculture at Laval and co-proprietor of Les Fraises de l’île d’Orléans, in a telephone meeting with Yahoo Canada. “It could be a characteristic item to help individuals who are fat or who could get to be diabetic.”

The Orleans is another strawberry cultivar (a licensed hereditary choice of strawberry) described by abnormally elevated amounts of polyphenols, which go about as hostile to oxidants to ensure cells and body chemicals against harm brought on by free radicals. Joined with polyphenols of cranberries, those of the Orleans strawberry are being utilized as a part of an item called GlucoPhenol, which makers case could be a more secure different option for metformin, a regularly utilized medication to treat Type 2 diabetes that helps control blood-glucose levels.

Despite the fact that metformin might likewise lessen the danger of building up the illness among individuals who are at danger, it can bring about symptoms, for example, lactic acidosis—a possibly life-debilitating condition- – and gastrointestinal issues.

While strawberries and strawberry concentrate may be useful to individuals with or at danger of diabetes, Joanne Lewis, chief of diabetes training at the Canadian Diabetes Association, suggests alert, as more research is required.

As per the Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes, Natural Health Products (NHPs)— which incorporate home grown drugs, vitamins, minerals and other fundamental supplements, probiotics and numerous other normally happening substances—are generally utilized, yet the confirmation of their viability in the counteractive action of diabetes is obscure.

Wound Care fastest growing negative pressure wound therapy pump company in the USA and Europe.

“Polyphenols and cell reinforcements are promising exacerbates that may help to control oxidative anxiety and aggravation, which may assume a part in lessening insulin resistance and the complexities of diabetes,” Lewis tells Yahoo Canada. “The long haul wellbeing and viability of these mixes are of concern. Nonetheless, it’s urging to see investigate that shows guarantee.”

Lewis says that the most ideal approach to diminish the danger of diabetes is to receive enhanced way of life propensities that outcome in a five to seven for every penny weight reduction through customary physical movement and good dieting.

All things considered, strawberries still make a decent nibble.

“When all is said in done, strawberries are an extraordinary decision for individuals with diabetes and individuals at danger for creating diabetes,” Lewis says. “A two-glass serving contains around 15 grams of accessible starch, contrasted with other organic product where a much littler part gives an equivalent

Halo XT NPWT Pump System

Northwest Florida Community Hospital Wound Healing Institute Celebrated 5th year anniversary

CHIPLEY – Northwest Florida Community Hospital’s Wound Healing Institute commended its five year commemoration Thursday, July 30. Guests were dealt with to refreshments and a voyage through the middle amid a drop-in style open house.

The organization opened its entryways in August 2010, conveying an end to a constrained drive for some zone inhabitants offering so as to look for tend to ceaseless injuries modified treatment regimens, complete treatments, and the most recent techniques and gear, including hyperbaric oxygen treatment.

Equinox Medical, LLC is a fastest growing negative pressure wound therapy pump and black foam wound dressing kit manufacturer.

The organization reported ($0.37) income per offer (EPS) for the quarter, hitting the agreement appraisal of ($0.37),

Macrocure (NASDAQ:MCUR) issued its quarterly income results on Tuesday. The organization reported ($0.37) income per offer (EPS) for the quarter, hitting the agreement appraisal of ($0.37), AnalystRatingsNetwork.com reports. Amid the same quarter a year ago, the organization posted ($0.59) EPS.

Shares of Macrocure (NASDAQ:MCUR) exchanged down 1.08% on Tuesday, coming to $13.69. 10,272 shares of the organization’s stock exchanged hands. The organization has a 50 day moving normal cost of $13.66 and a 200 day moving normal cost of $11.04. Macrocure has a 52 week low of $6.82 and a 52 week high of $16.10. The company’s business sector capitalization is $228.73 million.

Halo XT NPWT Brochure

Independently, Oppenheimer set a $20.00 target cost on shares of Macrocure and gave the stock a “purchase” rating in an exploration report on Wednesday, May thirteenth. Five examiners have evaluated the stock with a purchase rating, The organization at present has an agreement rating of “Purchase” and a normal value focus of $16.40.

Macrocure Ltd is an Israel-based regenerative prescription organization. The Company is centered around creating, assembling and commercializing cell treatment items to address unmet needs in the treatment of perpetual and other difficult to-mend wounds. Its item applicant, CureXcell, is a propelled injury care (NASDAQ:MCUR), treatment to treat such injuries by infusing living human white platelets that have been enacted to encourage the mending procedure. CureXcell is an injectable suspension of living human white platelets, including macrophages, neutrophils and lymphocytes, that are pivotal to starting, advancing and finishing the procedure of cell recovery and wound mending. The Company utilizes its cell enactment innovation to trigger these cells to discharge development components and other biochemical variables that enhance the recuperating environment in the injury quaint little inn wound conclusion.

Free Black Foam Wound Dressing Standard Application by Joey Mallari at Equinox Medical

Free Black Foam Wound Dressing Standard Application by Joey Mallari at Equinox Medical

Equinox Medical Black Foam Wound Dressing Standard Application

Negative Pressure Wound Therapy Black Foam Standard Application

Webinar: July 23, 2015
Time: 10:00 AM EST
Location: Online

Clinical Webinar covers the following:

  • Indication
  • Contraindication
  • Kit Content
  • How to cut the foam
  • How install the dome pad
  • How to use drape